Study of new drug BLEX 404 with docetaxel for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing whether adding a new study drug (BLEX 404) to the chemotherapy docetaxel is safe and effective for women with advanced or metastatic triple-negative breast cancer. The goal is to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged between 20 and 70.
- You have advanced or metastatic triple-negative breast cancer (meaning your cancer cells test negative for estrogen, progesterone, and HER2 receptors).
- You are planning to receive docetaxel chemotherapy as your treatment.
- Your general health and organ function (blood counts, liver, kidneys) are within adequate levels.
- You do not have brain metastases, autoimmune disease, HIV, or active infections.
- You have not previously been treated with taxane chemotherapy (like docetaxel or paclitaxel).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.